Federal Register / Vol. 62, No. 170 / Wednesday, September 3, 1997 / Notices 46503

The review criterion is proposed in

this combined notice, rather than

individual program announcements, to

provide consistent review of all primary

care medical education grant

applications. An announcement will be

made in the HRSA Preview for grant

programs which will conduct

competitive cycles in FY 1998.

The comment period is 30 days. All

comments received on or before October

3, 1997 will be considered before the

final review criteria are established.

Written comments should be addressed

to: Enrique Fernandez, M.D., Division of

Medicine, Bureau of Health Professions,

Health Resources and Services

Administration, Parklawn Building,

Room 9A–20, 5600 Fishers Lane,

Rockville, Maryland 20857, Telephone :

(301) 443–1467, FAX: (301) 443–8890.

All comments received will be

available for public inspection and

copying at the Division of Medicine, at

the above address, weekdays (Federal

holidays excepted) between the hours of

8:30 a.m. and 5:00 p.m.

Dated: August 28, 1997.

Claude Earl Fox,

Acting Administrator.

[FR Doc. 97–23373 Filed 9–2–97; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meeting

of the National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: Cancer Prevention Control

and Surveillance.

Date: September 15, 1997.

Time: 1 p.m. to adjournment.

Place: Teleconference, Executive Plaza

North, Conference Room E, 6130 Executive

Boulevard, Bethesda, MD 20852.

Contact Person: Courtney M. Kerwin,

Ph.D., M.P.H., Scientific Review

Administrator, National Cancer Institute,

NIH, Executive Plaza North, Room 630I, 6130

Executive Boulevard, MSC 7410, Bethesda,

MD 20892–7410, Telephone: 301/496–7421.

Purpose/Agenda: To evaluate and review

responses to Request for Proposal.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

The meeting will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Proposal and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the proposal, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control)

Dated: August 26, 1997.

LaVeen Ponds,

Policy Analyst, NIH, CMO.

[FR Doc. 97–23284 Filed 9–2–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: Evaluation of

Chemopreventive Agents by In vitro

Techniques.

Date: September 11–12, 1997.

Time: 9 a.m. to 5 p.m.

Place: Ramada Inn-Rockville, 1775

Rockville Pike, Rockville, MD 20852.

Contact Person: Lalita Palekar, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, 6130 Executive

Boulevard, North, Room 622B, Bethesda, MD

20892–7410, Telephone: 301/496–7575.

Purpose/Agenda: To evaluate and review

responses to a Request for Proposal.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.

Proposals and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control)

Dated: August 26, 1997.

LaVeen Ponds,

Policy Analyst, National Institutes of Health,

Committee Management Office.

[FR Doc. 97–23285 Filed 9–2–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: Clinical/Experimental

Radiation Research Studies (CERRIS).

Date: October 5–6, 1997.

Time: October 5—7:30 p.m. to 11 p.m.;

October 6—8 a.m. to 6 p.m.

Place: The Bethesda Ramada Hotel, 8400

Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Kevin Ryder, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, Executive Plaza North,

Room 611D, 6130 Executive Boulevard, MSC

7410, Bethesda, MD 20892–7410, Telephone:

301/402–2785.

Purpose/Agenda: To evaluate and review a

grant application.

The meeting will be closed in accordance

with the provision set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.

Application and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the application, the

disclosure of which would constitute a

clearly unwarranted invasion of personal

privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control)

Dated: August 26, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, National

Institutes of Health.

[FR Doc. 97–23287 Filed 9–2–97; 8:45 am]

BILLING CODE 4140–01–M